BioDiem

Executive Summary

BioDiem is an Australian biopharmaceutical company focused on licensing its Live Attenuated Influenza Virus (LAIV) technology for intranasal seasonal and pandemic influenza vaccines. The platform is utilized by partners in India, China, and the WHO to produce both egg-based and cell-based LAIV products, generating revenue through license fees and royalties. Founded in 2020 and headquartered in Melbourne, BioDiem operates as a private, commercial-stage company with 10-50 employees. Its business model capitalizes on the global demand for effective influenza vaccines, leveraging established manufacturing partnerships without the capital-intensive burden of in-house production. While the company has achieved commercial traction, its reliance on a single technology platform and partner revenues presents concentration risk. However, the growing emphasis on pandemic preparedness and intranasal vaccine delivery positions BioDiem favorably for future expansions into new geographies and formulation improvements. The company's technology is validated through WHO collaborations, underscoring its potential to address seasonal and pandemic influenza strains efficiently.

Upcoming Catalysts (preview)

• Q4 2026New licensing agreement in Southeast Asia or Latin America40% success
• Q1 2027WHO prequalification of a partner's LAIV product60% success
• Q3 2026Positive clinical data from partner on cell-based LAIV50% success